PFE.BA Pfizer Inc.
Company Analysis
Latest News
🟢 PFE.BA is trading 0.6% up today after EU approval of bladder cancer treatment combo
PFE.BA is trading 0.6% up today at $9405 after the European Commission approved a new bladder cancer treatment combination co-developed by the company. • The...
Pfizer and Merck Win EU Approval for First Bladder Cancer ADC Combo
The European Commission approved Pfizer and Merck’s combination therapy, Keytruda and Padcev, for a specific bladder cancer. This marks the first PD-1...
🟢 PFE.BA is trading 2.6% up today as shares rebound from a pullback following its IBRANCE FDA rally
PFE.BA is trading 2.6% up at $9370 as shares rebound from a two-day slide following a rally driven by positive regulatory news. • The stock's recent...
🔴 PFE.BA is trading 0% down today as shares ease following a rally on FDA approval for its IBRANCE regimen
PFE.BA is trading at $9135 (0%) as the stock stabilizes following a two-day slide that retraced gains from earlier in the week. • The recent volatility...
Pfizer Secures FDA Approval for IBRANCE, Expanding Market to All HER2 Statuses
Pfizer Inc. announced on June 25, 2026, that the FDA approved IBRANCE (palbociclib) for an expanded indication. This approval covers IBRANCE in combination...
🔴 PFE.BA declines 2.1% as Pfizer's Seagen-acquired lung cancer drug fails late-stage trial
PFE.BA is trading 2.1% down at $9415.00 today, following news that a key lung cancer drug candidate acquired through Pfizer's $43 billion Seagen acquisition...
Pfizer Pivots From M&A to AI, Navigating Looming Patent Cliffs
Pfizer is shifting its strategy from large-scale acquisitions to internal artificial intelligence integration. The company completed a $43 billion acquisition...
🔴 Pfizer Inc. is trading 2.6% down today as CFO Dave Denton steps down
Pfizer Inc. is trading 2.6% down today at $9505.00 following the announcement that its Chief Financial Officer, Dave Denton, will step down from his role...